Click image to view original image
1. Quick Detail:
Synonyms:Sildenafil citrate; viagra;
CAS Registry Number:171599-83-0
Assay:98%
MF:C28H38N6O11S
MW:666.7
Manufacturer :SUPER STEROIDS
Delivery time :within 18 hours upon receipt of payment
Delivery: EMS, DHL, TNT, FedEx, UPS
Appearance:White Solid
Usage:An orally active selective type 5 cGMP phosphodiesterase inhibitor
Biological Activity :Orally active, potent inhibitor of phosphodiesterase 5 (PDE5) (IC 50 = 4 nM). Enhances nitric oxide-dependent relaxation of human corpus cavernosum in vitro.
Other drugs in same class:Anastrozole,Letrozole,Tamoxifen citrate,Exemestane
2. Product description:
|
Product name |
Sildenafil Citrate |
|
Other name |
Sildenafil; Viagra; |
|
CAS register number |
171599-83-0 |
|
Molecular formula |
C28H38N6O11S |
|
Molecular weight |
666.7 |
|
Molecular structure |
|
|
Melting point |
187-189°C |
|
Assay |
98% |
3. Applications:
Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was originally discovered by Pfizer scientists Andrew Bell, David Brown, and Nicholas Terrett.
The primary indication of sildenafil is treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete intercourse). Its use is now standard treatment for erectile dysfunction in all settings, including diabetes.
In clinical trials, the most common adverse effects of sildenafil use included headache, flushing, dyspepsia, nasal congestion and impaired vision, including photophobia and blurred vision.Some sildenafil users have complained of seeing everything tinted blue (cyanopsia).Some complained of blurriness and loss of peripheral vision. In July 2005, the FDA found that sildenafil could lead to vision impairment in rare cases and a number of studies have linked sildenafil use with nonarteritic anterior ischemic optic neuropathy.
Rare but serious adverse effects found through postmarketing surveillance include priapism, severe hypotension, myocardial infarction (heart attack), ventricular arrhythmias, stroke, increased intraocular pressure, and sudden hearing loss. As a result of these postmarketing reports, in October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including sildenafil, required a more prominent warning of the potential risk of sudden hearing loss.
4.
COA:
|
Product name |
Sildenafil Citrate |
|
|
Appearance |
White crystalline powder |
|
|
Loss on drying |
≤1.0% |
0.3% |
|
Acidity |
3.0-5.0 |
4.1 |
|
Residue on ignition |
≤0.1% |
0.05% |
|
Heavy metals |
≤20ppm |
Complies |
|
Relevant impurity |
≤0.5% |
0.02% |
|
Methanol |
≤0.3% |
0.025% |
|
Methylene dichloride |
≤0.06% |
0.013% |
|
N,N-Dimethyl formamide |
≤0.088% |
Not detected |
|
Assay(on dried basis) |
≥98% |
98.4% |
